The Clinical Case for GLP-1 Maintenance Doses: Why Low-Dose Long-Term May Be Optimal

The standard GLP-1 prescribing model follows a predictable arc: start low, titrate up to the maximum tolerated dose, maintain until weight loss plateaus, and then... what? The emerging clinical consensus suggests that the "and then" may involve stepping down to a lower maintenance dose that preserves benefits while minimizing side effects, cost, and long-term medication burden.

The Maximum Dose Assumption

Clinical trials for GLP-1 weight management are designed to test the maximum approved dose — semaglutide 2.4 mg or tirzepatide 15 mg. This makes sense for trial design (it maximizes the treatment effect and the statistical signal), but it has created a clinical assumption that may not serve every patient optimally: that the maximum dose is the best long-term dose.

In practice, many patients achieve significant weight loss at intermediate doses and experience diminishing additional benefit as they titrate higher, while side effects continue to escalate. The question that a growing number of clinicians are asking is whether maintaining a lower dose after achieving target weight loss might offer a better risk-benefit balance for long-term therapy.

What the Evidence Suggests

Several lines of evidence support the maintenance dose concept:

The STEP 4 trial demonstrated that patients who were randomized to continue semaglutide 2.4 mg after 20 weeks of treatment maintained their weight loss, while those switched to placebo experienced significant regain. This established that ongoing treatment is necessary — but it didn't test whether a lower dose could maintain the benefit.

Real-world clinical experience has been more nuanced. Many obesity medicine specialists report successfully maintaining patients on doses below maximum — semaglutide 1.0-1.7 mg or tirzepatide 5.0-10.0 mg — after achieving their weight loss goals. These patients maintain most of their weight loss with fewer side effects, lower medication costs, and better long-term adherence.

The dose-response curve for GLP-1 medications is not linear. The difference in average weight loss between semaglutide 1.0 mg and 2.4 mg is approximately 5-7 percentage points. For a patient who has already lost 15% of their body weight on the higher dose and is now in maintenance, that marginal benefit may not justify the additional side effect burden and cost.

How Maintenance Dosing Works in Practice

For patients and providers considering a maintenance dose reduction, here's the general framework that experienced clinicians follow:

Timing: Most clinicians wait until the patient has been weight-stable (within 3-5 pounds of goal) for at least 3-6 months at their current dose before considering reduction. Attempting to reduce too early — while the patient is still actively losing — often leads to rebound weight gain.

Step-down approach: Rather than dramatic dose cuts, the preferred method is to step down one dose level at a time (e.g., from semaglutide 2.4 mg to 1.7 mg) and hold at each step for 6-8 weeks while monitoring weight and metabolic markers. If weight remains stable, another step down can be considered.

The floor: Most clinicians find that there's a minimum effective dose below which weight regain begins. For semaglutide, this is often in the 0.5-1.0 mg range. For tirzepatide, 5.0-7.5 mg. Below these levels, the appetite-suppressing effects may be insufficient for maintenance in most patients.

Course correction: If weight begins to increase at a lower dose, stepping back up to the previous effective dose is appropriate. This isn't failure — it's evidence-based adjustment. The optimal maintenance dose is the lowest dose that maintains weight stability and metabolic health.

Financial and Practical Benefits

Lower maintenance doses offer tangible benefits beyond clinical considerations. For patients paying out of pocket, the cost difference can be substantial — some compounding pharmacies price by dose level, and lower doses mean lower monthly costs. Insurance plans with tiered copays may also charge less for lower doses.

Side effect burden tends to correlate with dose. Patients on maintenance doses frequently report improved quality of life compared to their maximum-dose phase — less nausea, more normal eating patterns, fewer dietary restrictions, and better social flexibility around food.

Adherence also improves at lower doses. When the side effect burden is lower and the cost is more manageable, patients are more likely to continue treatment consistently — which is ultimately the most important factor for long-term weight maintenance.